KB-1093

MPDL3280A-mIgG1-D265A

46631

Home » MPDL3280A-mIgG1-D265A

Background of MPDL3280A-mIgG1-D265A

Atezolizumab, also known as MPDL3280A, a high affinity-specific against PD-L1, is FDA approved for use in metastatic NSCLC after disease progression on platinum-containing chemotherapy. However, as it is a humanized antibody, it is immunogenic in mice. To overcome this issue, MPDL3280A-mIgG1-D265A was generated by recombinant DNA technology . Importantly, its constant region contains a point mutation D265A (a replacement of aspartic acid by alanine at position 265), resulting in the complete loss of cytolytic effector functions.

Specifications

Catalog Number	KB-1093
Antibody Name	MPDL3280A-mIgG1-D265A
Isotype	Mouse IgG1,kappa
FC Muations	D265A
Target	PDL1
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Cortinovis D, von Pawel J, Syrigos K, et al. Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: safety population analyses from the Ph III study OAK. Ann Oncol 2017;28:v468–96.
Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837–46.